GlassScriptPhysician profile
Stephen Craig Merrell
NPI 1003174129
$5,325.47
in general payments reported to CMS, 2019-2025
48 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $402 · 2021: $798 · 2022: $923 · 2023: $1,196 · 2024: $1,142 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.54 | 2021-2025 | |
| Lilly USA, LLC | $466.49 | 2020-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $460.18 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $388.27 | 2020-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.63 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $288.43 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $248.16 | 2021-2025 | |
| Astellas Pharma US INC | $224.48 | 2020-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $221.61 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $129.75 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $93.87 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $88.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $75.87 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $73.34 | 2022-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $71.02 | 2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $65.23 | 2022-2024 | Heplisav-B |
| Axsome Therapeutics, INC. | $63.34 | 2025 | Sunosi, Auvelity |
| Organon LLC | $62.29 | 2022-2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.32 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.72 | 2021-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $51.01 | 2022 | |
| Exact Sciences Corporation | $49.52 | 2023 | Cologuard Collection Kit |
| Cranial Technologies, INC | $48.32 | 2020-2024 | Doc Band |
| Amgen INC. | $44.98 | 2021-2024 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $44.31 | 2024-2025 | Voquezna |
| Biomerieux INC | $44.00 | 2025 | Biofire Spotfire Control Station |
| Alkermes, INC. | $42.75 | 2022-2023 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.82 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $37.94 | 2023 | Trudhesa |
| Shield Therapeutics INC | $37.03 | 2023-2024 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $28.59 | 2022 | |
| Lucid Diagnostics INC. | $25.32 | 2022 | |
| Antares Pharma, INC. | $24.32 | 2021 | |
| Seqirus USA INC | $21.22 | 2024 | Flucelvax, Fluad |
| Becton, Dickinson and Company | $18.02 | 2024 | Bd Surepath Collection Vial |
| Ani Pharmaceuticals, INC. | $17.63 | 2025 | Purified Cortrophin Gel |
| Lundbeck LLC | $17.35 | 2022 | |
| Almatica Pharma LLC | $17.23 | 2023 | Loreev Xr |
| Ultragenyx Pharmaceutical INC. | $16.92 | 2022 | |
| Allergan, INC. | $15.83 | 2020 | |
| Rgh Enterprises LLC | $15.19 | 2025 | |
| Sumitomo Pharma America, INC. | $14.49 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $14.17 | 2025 | |
| Daiichi Sankyo INC. | $13.93 | 2020 | |
| Baxter Healthcare | $13.84 | 2023 | Hillrom - Life 2000 Ventilation System |
| Currax Pharmaceuticals LLC | $13.17 | 2024 | Onzetra Xsail, Contrave |
| Merck Sharp & Dohme LLC | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Merrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.